Accustem Sciences Inc
accustem.comAccustem Sciences Inc (OTC: ACUT) is a pre-commercial diagnostics company developing in vitro diagnostic (IVD) tests for disease detection. The company has not yet generated product revenue as of the 10-K filed April 14, 2026, and remains dependent on completing clinical trials and obtaining regulatory marketing approvals before commercializing its diagnostic tests. ACUT's common stock trades on the OTC Markets. Leadership includes Wendy Blosser as Chief Executive Officer, Joe Flanagan as Chief Business Officer, and Jeff Fensterer as Chief Operating Officer. The company faces regulatory oversight from the FDA under its IVD framework, as well as potential EU IVDR certification requirements. No sales or marketing infrastructure is in place as of the filing date, and the company acknowledges it will need to build or partner for commercial distribution if and when its tests receive approval.
Products & Services
In vitro diagnostic (IVD) tests in clinical development, including laboratory-developed tests (LDTs) subject to FDA regulatory oversight. No approved or commercially available products as of the filing date.
Revenue Model
No product revenue reported as of the 10-K filed April 14, 2026. The company is pre-revenue, funded through equity, and has not yet commercialized any diagnostic test.
Customers & Markets
Intended end markets include physicians, patients, and third-party payers in the medical community. No commercial customers as of the 10-K filed April 14, 2026.
Geographic Exposure
Primarily U.S.-focused regulatory pathway via FDA. EU market referenced through IVDR notified body certification requirements. No commercial operations in any geography as of the filing date.
Financial Snapshot
Loading...
